Search results for ibm

Clinicians and scientists meet to discuss new guidelines for IBM diagnosis and treatment

The outcomes of a London inclusion body myositis (IBM) workshop have been published in the medical journal Neuromuscular Disorders by Dr David Hilton-Jones from the Oxford Muscular Dystrophy Campaign Muscle and Nerve Centre, Prof....

Orphazyme sponsors IBM trial at University College London

Danish biotech company, Orphazyme, has assumed sponsorship of a phase 2/3 trial assessing the safety and efficacy of arimoclomol for the treatment of sporadic inclusion body myositis (sIBM)....

Results from Orphanzyme inclusion body myositis (IBM) clinical trial

At the end of March the biotech company Orphanzyme announced negative results from its Phase 2/3 clinical trial testing arimoclomol for the treatment of inclusion body myositis (IBM)....

IBM trial starts in the UK

We’re pleased to let you know that the Institute of Neurology at University College London (UCL) is recruiting for Orphazyme’s  inclusion body myositis (IBM) trial....

Follistatin gene therapy improves muscle function of people with IBM

Promising results from a phase 1 trial for sporadic inclusion body myositis (sIBM) have been published in the scientific journal, Molecular Therapy. The trial tested the safety of a follistatin gene therapy....

Researchers uncover potential treatment for inclusion body myositis

Inclusion body myositis (IBM) is the most common neuromuscular condition to affect the elderly. Individuals affected by IBM experience a slow progression of muscle weakness and wasting in the arms and legs....

IBM drug receives Fast Track designation

Orphazyme have announced that the U.S Food and Drug Administration (FDA) have granted the drug, arimoclomol, Fast Track designation. The drug has been developed as a potential treatment for sporadic inclusion body myositis (sIBM)....

New inclusion body myositis alert card launched

Muscular Dystrophy UK’s Outreach team is pleased to announce the launch of a new alert card for people with inclusion body myositis (IBM)....

Developing best practice guidelines for inclusion body myositis

Do you have sporadic inclusion body myositis (IBM)? An international team developing best practice guidelines would like to hear from you....

News

Near you

Find support and services in your area:

Keep in touch